Completed OBSERVATIONAL NCT06159231

FAME II-10-year Follow-Up (FAME2-10yFU)

Fractional Flow Reserve-guided Percutaneous Coronary Intervention Plus Optimal Medical Treatment Versus Optimal Medical Treatment Alone in Patients with Stable Coronary Artery Disease - FAME II, a 10-year Follow-up Study.

Sponsor: Abbott Medical Devices

Conditions Coronary Artery Disease

Updated 5 times since 2024 Last updated: Jan 6, 2025 Started: Apr 25, 2023 Primary completion: May 15, 2024 Completion: May 15, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Coronary Artery Disease and is currently completed. Abbott Medical Devices leads this study, which shows 5 recorded versions since 2023 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed
Feb 2025 — Sep 2025 [monthly]

Completed

Status: Recruiting → Completed
Sep 2024 — Feb 2025 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Jan 2024 — Jul 2024 [monthly]

Recruiting

First recorded

Apr 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott Medical Devices
CoreAalst BV

Data source: CoreAalst BV

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalst, Belgium , Bangor, United States , Brno, Czechia , Bron, France , Budapest, Hungary , Cona, Italy , Copenhagen, Denmark , Decatur, United States , Eindhoven, Netherlands , Kragujevac, Serbia and 6 more locations